FDA approves mRNA flu vaccine mFlusiva, but CDC won't recommend it

The FDA granted full approval to mFlusiva, the first mRNA-based flu vaccine, for adults aged 50–64. The CDC kept last year's flu vaccine recommendations citing "legal uncertainties," so mFlusiva is absent from this fall's public list, though medical societies recommend it as an option.

• mFlusiva is the first mRNA flu vaccine, approved by the FDA for ages 50–64
• CDC kept last year's recommendations citing "legal uncertainties and inquiries"
• The ACIP advisory committee was halted by a court after Kennedy's overhaul
• Medical societies recommend the shot and insurers still pay for it